April 1st Week, 2026 Regulatory Events   🎯 The EC approved Merck & Co./ MSD 's pembrolizumab (anti-PD-1) + paclitaxel ± bevacizumab for the Tx of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults with PD-L1 CPS ≥1, and who have received one or two prior systemic Tx regimens (Ref 1)  ❓ How is the regimen positioned in EU market landscape?   Special Designations    ⭐ The US FDA granted the breakthrough therapy designation to  Fore